Related Posts with Thumbnails     Say遊記     奇美醫院        食品藥物消費者知識服務網    台灣藥事資訊網    正確用藥數位資訊學習網
柳營奇美醫院24小時藥物諮詢電話:06-6226999-77119 email:clh5500@mail.chimei.org.tw

目前日期文章:200808 (5)

瀏覽方式: 標題列表 簡短摘要

藥品新增

<24R041> Rivastigmine (Exelon ® ) 4.5mg/ Cap.

新藥介紹

<24R041> Rivastigmine (Exelon ® ) 4.5mg/ Cap.

作用機轉/

藥理作用

Rivastigmine, a reversible inhibitior of cholinesterase, increases

the level of acetylcholine available in the CNS.

適應症/劑量

PO,

Adult

Alzheimer's dementia: 1.5 mg BID initially, if well tolerated, the dose may be increased to 3 mg BID after a minimum of 2 wks; subsequent increases to 4.5 mg BID and 6 mg BID should be attempted after a minimum of 2 wks at the previous dose. Max. 12mg/d.

Pediatric

Safety and efficacy in children have not been established .

注意事項

Take after or with meals.

使用禁忌

hypersensitivity to rivastigmine, carbamate derivatives, or other components of the product

不良反應

M: Diarrhea/constipation, nausea, vomiting, flatulence, loss of appetite, indigestion, abdominal pain; weight loss; dizziness, tremor, asthenia; UTI.

L or R: hypertension; influenza-like illness.

懷孕危險分級

B

健保規範

 

 

 

24R041.JPG 

1.經神經科或精神科醫師依NINDS-ADRDA或DSM或ICD標準診斷為輕度至中度之失智症(MMSE 10~26分或CDR 1級及2級)患者使用。並檢附MMSE或CDR智能測驗結果。

2.使用後每六個月需重新評估,追蹤MMSE或CDR智能測驗,如MMSE較起步治療時減少2分(不含)以上或CDR退步1級,則應停用。

3.如有腦中風病史,臨床診斷為「血管性失智症」,或有嚴重心臟傳導阻斷(heart block)之病患,不建議使用。

4.需經事前審查核准後使用,第一次申請需檢附以下資料:

(1)CT、MRI或哈金斯氏量表(Hachinskki lschemic Scale)三項其中之任一結果報告。

(2)CBC,VDRL,BUN,Scr,GOT,GPT,T4,TSH檢驗。

(3)病歷摘要。

(4)阿茲海默氏症診斷準則。(95/6/1)

(5)MMSE或CDR智能測驗報告。

藥劑科   啟

Sam080477 發表在 痞客邦 PIXNET 留言(0) 人氣()

藥品異動通知及新藥介紹

一、 藥品刪除

<33C047> Cromolyn( Allergocrom) oph(點眼液)2%

< 23S082> Trifluoperazine (Stelazine)5mg

二、 藥品新增

<39E023> Emedastine Difumarate (Emadine ® ) Oph. sol'n 0.05%, 5ml/Btl

<13O001> Olanzapine(Zyprexa) 10mg/V Inj.

三、 新藥介紹

<39E023> Emedastine Difumarate (Emadine® ) Oph. sol'n 0.05%, 5ml/Btl

作用機轉/

藥理作用

Emedastine difumarate, a selective H(1) histamine receptor

inhibitor, antagonizes histamine-stimulated vascular

permeability in the conjunctiva when given topically to the eyes.

適應症/劑量

Oph solution,

Adult and Pediatric3yrs

Allergic conjunctivitis: 1drop BID-QID.  

給藥注意事項

Remove contact lenses prior to instillation; may reinsert after 10 min of administration.

使用禁忌

hypersensitivity to emedastine products.

不良反應

Headache; taste disturbance; blurred vision, keratitis, dry eyes,

ocular burning/stinging, corneal infiltrates, corneal staining,

foreign body sensation; rhinitis, sinusitis; hyperemia.

懷孕危險分級

B

健保規範

無相關規定

藥品圖檔

39E023.JPG 

新藥介紹

<13O001> Olanzapine (Zyprexa® ) Inj., 10mg/Vial

作用機轉/

藥理作用

Olanzapine is a thienobenzodiazepine used to treat emotional and mood disorders.

The proposed mechanism of antipsychotic activity is mediated through a combination of dopamine and serotonin type 2 antagonism.

適應症/劑量

IM,

Adult

Agitation associated with schizophrenia and bipolar I mania:

2.5- 10 mg as a single dose initially. If agitation warranting, additional doses up to 10 mg may be given after 2hrs.

Max. 3 doses/day. 20mg/day.

Patients be assessed for orthostatic hypotension prior to each subsequent IM administration

 

Pediatric

Safety and efficacy have'nt been established.

給藥注意事項/儲存方式

  • 1) 1) Store Zyprexa® vial below 25°C. Protect from light.
  • 2) 2) Dissolve 10mg vial with 2.1 mL of Sterile Water for Injection for IM injection immediately (within 1 hour).
  • 3) 3) Discard any unused portion of reconstituted Zyprexa®.

使用禁忌

known hypersensitivity to olanzapine product,

narrow-angle glaucoma.

不良反應

M: Agitation; akathisia; EPS; personality disorder; abnormal gait; vision change; asthenia; GI upset; dizziness; dry mouth; headache; weight gain; postural hypotension; rhinitis; somnolence; speech disorder; tremor.

L: chest pain; dyskinesia; dystonic; flu-like symptoms; hypertension; mood or mental changes; twitching; vaginitis; acne; articulation impairment; dry skin; dysmenorrheal; edema; extremity pain; hypertonia; hypotension; increased appetite; increased cough; increased salivation; insomnia; N/V; paresthesia; pharyngitis; stuttering; sweating; tachycardia; thirst; urinary incontinence; weight loss.

R: Dyspnea; menstrual changes; skin rash; ventricular extrasystoles; water intoxication; decreased libido; diplopia; photosensitivity.

懷孕危險分級

C

健保規範

1.本類製劑之使用需合乎衛生主管機關許可之適應症範圍,並需符合下列條件:

(1)開始使用「第二代抗精神病藥品」時需於病歷記載醫療理由或診斷,以及臨床整體評估表(Clinical Global Impression,簡稱CGI)之分數。

(2)經規則使用六至八週後,需整體評估其療效,並於病歷

記載臨床整體評估表之分數。

(3)日劑量超過20 mg/day時,須於病歷記載理由:

2.本類藥品不得使用於雙極性疾患之鬱症發作。

3.olanzapine用於預防雙極性疾患復發時,限lithium、carbamazepine、valproate等藥品至少使用兩種以上,治療無效或無法耐受副作用時使用。

藥品圖檔

13O001.JPG 

 

 

 

藥劑科   啟

Sam080477 發表在 痞客邦 PIXNET 留言(0) 人氣()

藥品異動通知及新藥介紹

一、 藥品新增

<23C159> Cetirizine (Alltec® ) Oral Sol'n 1mg/ ml, 60ml/Btl

<23L136> Loratadine (Mintapp® ) (Clarityne®) Syrup 1mg/ ml, 30ml/Btl

二、 新藥介紹

<23C159> Cetirizine (Alltec ® ) Oral Sol'n 1mg/ ml, 60ml/Btl

作用機轉/

藥理作用

Cetirizine hydrochloride, a metabolite of hydroxyzine,

selectively blocks peripheral histamine H(1)-receptor activity .

適應症/劑量

PO,

Adult & Pediatric

Seasonal or perennial allergic rhinitis; Chronic urticaria:

Adult and pediatric≧6yrs: 5-10ml QD.            

Pediatric:

6-23 mo, 2.5 ml QD;  2-5 yrs, 2.5-5 ml QD. Max.5ml/day

注意事項

Take without regard to food.

使用禁忌

hypersensitive to cetirizine, hydroxyzine, or any ingredient in the formulation.

不良反應

M: Drowsiness; dry mouth.

L or R: Blurred vision; confusion; difficult or painful urination;

dry nose or throate; tachycardia; photosensitivity; dizziness;

increased sweating; anorexia; ringing or buzzing in ears;

nightmares; skin rash; unusual excitement, nervousness,

restlessness or irritability.

懷孕危險分級

B

健保規範

無相關規定

藥品圖檔

23C159.JPG 

<23L136> Loratadine (Mintapp® )(Clarityne®) Syrup 1mg/ ml, 30ml/Bt

作用機轉/

藥理作用

Loratadine, a long-acting tricyclic antihistamine, selectively

blocks peripheral histamine H(1)-receptor activity .  

適應症/劑量

PO,

Adult & Pediatric

Allergic rhinitis:

Adult and pediatric≧12yrs: 10 mg QD.            

Pediatric 2-12 yrs,

B.W. >30kg: 10 mg QD.

B.W.≦30kg: 5mg QD.

注意事項

Take without regard to food.

使用禁忌

 hypersensitivity to loratadine or any of its ingredients

不良反應

M: Drowsiness; dry mouth.

L or R: Blurred vision; confusion; difficult or painful urination;

dry nose or throate; tachycardia; photosensitivity; dizziness;

increased sweating; anorexia; ringing or buzzing in ears;

nightmares; skin rash; unusual excitement, nervousness,

restlessness or irritability.

懷孕危險分級

B

健保規範

無相關規定

藥品圖檔

23L136.JPG 

 

 

 

藥劑科   啟

Sam080477 發表在 痞客邦 PIXNET 留言(0) 人氣()

 藥品異動通知及新藥介紹

一、 藥品刪除

<17I231> Insulin Glargine (Lantus® ) Inj., 1000IU/ 10ml/Vial

二、 藥品新增

<17I265> Insulin Glargine (Lantus® ) SoloStar® Pen Inj., 300IU/ 3ml/Pen

<23A240> Atomoxetine HCl (Strattera ® ) 40mg/ Cap.

 

三、 藥品外觀、外包裝變更

變更品項:<24I109> Irbesartan PO ;

< 26D049> Mebeverine PO

<31Z026> Acyclovir Cream

四、 新藥介紹

<17I265> Insulin Glargine (Lantus®) SoloStar® Pen  300IU/ 3ml/Pen

作用機轉/

藥理作用

 

Lantus®, a recombinant long-lasting human insulin analog, regulates glucose metabolism.

In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism.

In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat.

Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain.

適應症/劑量

SC,

Adult and Pediatric6yrs

DM: Individualized dosage QD at the same time every day.

注意事項

1) Roate the injection site to reduce the risk of lipoatrophy.

2) Store the unopened Lantus® SoloStar® Pen in a refrigerator at 2 - 8°C.

The opened (in-use) SoloStar® Pen should not be refrigerated. Store the opened (in-use) SoloStar® Pen below 25°C away from direct heat and light, and discard after 28 days.

使用禁忌

hypersensitivity to any components of insulin glargine product.

不良反應

M: Hypoglycemia; weight gain.

R: Edema; lipoatrophy/ lipohypertrophy at injection site.

懷孕危險分級

C

健保規範

無相關規定。

   

原<17I231> Insulin Glargine (Lantus®) Inj.,1000IU/ 10ml/Vial

品項刪除。

藥品圖檔

17I265.JPG 

 

<23A240> Atomoxetine HCl (Strattera ® ) 40mg/ Cap.

作用機轉/

藥理作用

 

Atomoxetine, a selective norepinephrine reuptake inhibitor,

produces therapeutic effects in patients with

Attention-Deficit/Hyperactivity Disorder (ADHD). The exact

mechanism is yet to be determined .

適應症/劑量

PO,

Adult

Attention-deficit hyperactivity disorder:

40 mgQD; increase after a minimum of 3 days to a target dose of approximately 80 mg/day in 1-2 divided doses; 100 mg/day may be considered after 2 to 4 additional wks in patients who have not achieved adequate response on lower doses. Max. 100 mg/d.

Pediatric ≥ 6 yrs

Attention-deficit hyperactivity disorder:

up to 70 kg, 0.5 mg/kg/day; increase after a minimum of 3 days to a target dose of 1.2 mg/kg/day; 1.4 mg/kg/day or 100 mg (whichever is less).

over 70 kg, the same as adult.

使用禁忌

hypersensitivity to atomoxetine product;

MAO inhibitors (atomoxetine should not be administered during therapy with or within 2 weeks of discontinuing an MAOI);

narrow angle glaucoma (increased risk of mydriasis).

給藥注意事項

Take with or without food.

Swallow the capsule whole. Do not crush, break, or chew it.

不良反應

M or L: Hypertension, palpitation, tachycardia; weight loss; rash; constipation, nausea, vomiting, indigestion, loss of appetite, xerostomia; dizziness, headache, insomnia, paresthesia, somnolence; mood swings; difficulty passing urine, urinary retention; disorder of ejaculation, dysmenorrhea, erectile dysfunction, prostatitis, reduced  libido.   

R: Injury of liver; dyskinesia, seizure; suicidal thoughts;

priapism.

懷孕危險分級

C

健保規範

1)限6-18歲(含),依DSM或ICD標準診斷為注意力不全過動症患者且對短效型methylphenidate(如Ritalin)治療之副作用無法耐受,或治療一個月以上,療效不佳者使用,並於病歷上記載使用理由。

2)如符合前項規定且已使用本類藥品治療半年以上,而18歲後仍需服用者,需於病歷上詳細記載以往病史及使用理由。

3)atomoxetine HCl原則上每日限使用1粒,惟每日劑量需超過60mg時,應於病歷中記載理由,則每日至多可使用2粒,每日最大劑量為100mg。(97/5/1)

藥品圖檔

 23A240.JPG

 

藥品外觀、外包裝變更

<24I109>主成份:

Irbesartan

新藥品

舊藥品

中文名

安普諾維膜衣錠

英文名

Aprovel F.C.Tab.

健保代碼

B022551100

含量/規格        

150mg/ F.C.Tab.

衛署許可證之適應症

本態性高血壓之治療。治療併有高血壓及第二型糖尿病患者的高血壓及糖尿病性腎病變。

使用方法

口服。成人常用劑量:每日1次,每次1-2粒。

藥商/製造廠

賽諾菲安萬特/ SANOFI WINTHROP INDUSTRIE 

藥品圖檔

23I109N.JPG 

23I109O.JPG 

 

<26D049>主成份:

Mebeverine

新藥品

舊藥品

中文名

肚比康糖衣錠

肚痊寧糖衣錠

英文名

Dobecon S.C.Tab.

Duspatalin S.C.Tab.

健保代碼

A045247100

B000700100

藥商/製造廠

永信/永信

友信/INTERPHIL LAB, INC.

含量/規格

100mg/ S.C.Tablet

衛署許可證之適應症

原發性續發性結腸過敏合併症、腸憩室炎、腸憩室形成及區域性腸炎、膽胰運動困難、胃潰瘍、消化器管炎症 。 

使用方法

口服。 空腹或依醫囑指示服用。 

成人常用劑量:每日4次,每次1粒。

藥品圖檔

26D049N.JPG 

26D049O.JPG 

       

          

<31Z026>主成份:

Acyclovir

新藥品

舊藥品

中文名

力克乳膏

英文名

DEVIRUS CREAM

健保代碼

A033590319

含量/規格        

5%; 4gm/ Tube

衛署許可證之適應症

單純疱疹病毒引起之皮膚感染。 

使用方法

塗抹皮膚或口腔黏膜用。每日5次,約間隔4小時塗抹,連續使用5-10天。

藥商/製造廠

溫士頓/溫士頓

藥品圖檔

31Z026N.JPG 

31Z026O.JPG 

 

 

 

藥劑科   啟

Sam080477 發表在 痞客邦 PIXNET 留言(0) 人氣()

健保給付規定修訂

修訂品項<26V003> Vioment® Tablet

 

實施日期9781日起

 

修訂內容

 

<26V003 > Vioment® Tablet

修正後給付規定

原給付規定

7.3.2.益生菌類藥物Antidiarrheal microorganisms

限用於接受放射治療、化學療法患者,治療期間

造成的腹瀉。

無相關規定

※劃線部份為增修規定。

備註:劃線部份為增修規定。

 

 

 

藥劑科  

Sam080477 發表在 痞客邦 PIXNET 留言(0) 人氣()

找更多相關文章與討論